In IgA Nephropathy #IgAN, is "hematuria" a marker of active inflammation 🔥
Is "hematuria" a marker of active inflammation in IgA Nephropathy?
Definition:
Hematuria refers to the presence of red blood cells (RBCs) in urine, which can be gross (visible to the eye) or microscopic (detectable only under a microscope).
Evidence-based Analysis
Hematuria as a Hallmark of IgAN Pathophysiology
Hematuria, either macroscopic or microscopic, is a hallmark of IgA nephropathy (IgAN), arising due to immune complex-mediated injury to the glomerular capillary wall, resulting in inflammation and erythrocyte leakage into the urinary space[1]. Experimental and clinical studies confirm that hematuria frequently appears after IgA-containing complexes deposit in the glomerulus, activate inflammation and complement pathways, and trigger capillary wall damage[2].
Association with Active Inflammation
Hematuria mechanistically reflects ongoing glomerular capillary inflammation. Detection of dysmorphic RBCs (from glomerular origin) in the urine supports the concept that hematuria signals inflammatory injury in the glomerulus. Episodes of hematuria typically correlate with active glomerular lesions, such as mesangial hypercellularity or cellular crescents, rather than only chronic scarring[3], and are often accompanied by evidence of continued immune activation[e.g.], [ crescentic formation], [ complement deposits][2].
Recent studies have demonstrated that:
- Hematuria intensity can decline after effective anti-inflammatory treatment, consistent with reduced glomerular inflammation upon intervention[3].
- Persistently active mesangial lesions on biopsy are associated with ongoing hematuria, further suggesting hematuria reflects clinical disease activity rather than just chronic changes[7].
- Animal and human biopsy evidence demonstrates that the glomerular capillary wall is injured by immune deposits, complement, and inflammatory cell infiltration, evidenced by hematuria concurrent with activity on renal histology[8].
Persistence and Chronicity: Value as a Biomarker
While hematuria is a sensitive indicator of active inflammation, its specificity and predictive value for long-term outcomes or progression in IgAN are debated. Earlier lack of standardized measurement and day-to-day variability led many clinical studies to rely on proteinuria and renal function for risk stratification[1]. However, more recent systematic and automated approaches to hematuria assessment have linked persistent microscopic hematuria to greater risk of ongoing inflammatory activity, histological lesions, and possibly to progression[2], though this is not universal across studies[9].
Important Nuances:
- Hematuria can persist even in the absence of overt active lesions, due to chronic structural changes like glomerular basement membrane fragility, so the context (recent onset, persistent rise, or decline with therapy) matters for interpretation[10].
- Some evidence points to persistent microscopic hematuria as a risk factor for progressive decline in renal function, particularly when associated with other active markers (e.g., proteinuria, declining eGFR)[11]. Others have found less clear associations, stressing the need for standardized methodologies and controls for confounding variables[9].
Mechanistic Insights:
- The pathogenesis of hematuria involves immune complex (IgA)-triggered injury, with subsequent capillary wall damage and oxidative stress.
- Macrophage and complement infiltration into glomeruli are strongly linked to both hematuria and mesangial proliferation, underlining inflammation as a central driver[12].
- Interventional studies demonstrate that therapies targeting immune-inflammatory pathways (e.g., tonsillectomy plus steroids) reduce hematuria alongside markers of cytokine-driven inflammation[13].
Integrated Summary
In IgA nephropathy, hematuria—particularly when new in onset, persistent, or fluctuating in parallel with other signs of disease activity—is generally considered a marker of active glomerular inflammation. Its appearance and persistence are physiologically linked to inflammatory and immune mechanisms causing capillary wall injury[1], [10], [7]. However, due to methodological challenges and the contribution of chronic damage to ongoing hematuria, interpretation in isolation (i.e., without considering proteinuria, eGFR trends, biopsy findings, and therapeutic context) must be cautious[9].
Routine, standardized tracking of hematuria over longitudinal follow-up is gaining acceptance as a means of better capturing disease activity and response to therapy in IgAN[2], [11]. Emerging studies encourage the inclusion of hematuria as a secondary marker in clinical decision-making and trial enrollment, especially in the context of other evidence of active disease or inflammation[2], [13], [3].